Form 4: Kymera Director Exercises Options, Sells Shares

Kymera Therapeutics Director Jeffrey W. Albers exercised 5,000 stock options and subsequently sold all 5,000 shares of common stock on December 8, 2025, under a pre-arranged trading plan.

Summary

• Director Jeffrey W. Albers of Kymera Therapeutics, Inc. exercised 5,000 stock options for common stock at an exercise price of $14.18 per share.
• Immediately following the exercise on December 8, 2025, Albers sold all 5,000 acquired shares of common stock in two separate transactions.
• The first sale involved 2,748 shares at a weighted average price of $89.323 per share, with individual transaction prices ranging from $89.17 to $89.51.
• The second sale involved 2,252 shares at a weighted average price of $90.3035 per share, with individual transaction prices ranging from $90.27 to $90.67.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2024.
• Following these transactions, Albers directly owns 0 shares of common stock and retains 7,000 stock options, which are fully vested and exercisable with an expiration date of June 15, 2032.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a director selling shares can sometimes be seen negatively, the fact that it's an option exercise and immediate sale under a 10b5-1 plan mitigates concerns. The director realized a significant gain, which is positive for the individual, but the net effect on company sentiment is minimal as it's a pre-planned personal financial event.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, which indicates pre-planned sales and helps mitigate concerns about insider trading based on non-public information.
• The director realized a substantial gain, as the sale prices (weighted averages of $89.323 and $90.3035) were significantly higher than the exercise price of $14.18 per share.

Negatives

• A director selling a significant number of shares (5,000) could be perceived negatively by the market, potentially signaling a lack of confidence, although this is largely mitigated by the pre-arranged 10b5-1 plan.
• The director's direct beneficial ownership of common stock is now 0 shares, though they still hold 7,000 stock options.

Future Outlook

NA

Industry Context

This is a routine insider transaction filing (Form 4) and does not inherently provide direct insights into broader industry trends or the competitive landscape. It reflects an individual director's personal financial planning.

Stakeholder Impact

• Shareholders: The sale of shares by a director, even under a 10b5-1 plan, could be interpreted by some as a slight negative signal, though the impact is generally minimal for routine, pre-planned transactions.
• Employees: No direct impact.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Key Dates

Recommendation

This Form 4 filing details a pre-planned insider transaction where a director exercised stock options and immediately sold the acquired shares. Such transactions, executed under a Rule 10b5-1 plan, are typically routine and do not reflect new information about the company's prospects. While the director realized a substantial gain, the transaction itself provides no new fundamental insights to warrant a change in investment recommendation. Investors should continue to 'hold' based on the company's underlying business fundamentals rather than this specific insider filing.

Keywords

Kymera Therapeutics, KYMR, SEC Form 4, Insider Transaction, Stock Option Exercise, Share Sale, Jeffrey W. Albers, Director Transaction, 10b5-1 Plan